ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Imatinib Induced Thyroid Dysfunction in BCR::ABL1 Positive Chronic Myeloid Leukaemia Patients: Sokal Score as a Predictor.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid dysfunction has been reported as an adverse effect of imatinib mesylate. However, the risk factors associated with this adverse effect in CML patients have not been elucidated. We investigated the baseline parameters (Age, BCR::ABL1 ratio, Sokal, Hasford, and EUTO scores) of the CML patients as predictors of thyroid dysfunction. This longitudinal study included 50 Imatinib naïve CML patients. Serum TSH, fT3, and fT4 were done for each subject at recruitment and 1, 3, and 6 months on Imatinib. These patients were classified into CML1(patients who remained euthyroid) and CML2(patients with thyroid dysfunction). The relationship of these parameters with the serum TSH and the difference between the two groups were determined. Thyroid dysfunction was observed in 7 patients (6 females and 1 male) at 6 months only. The mean ± SD of the PCV, Sokal score and Hasford scores of the two groups (CML1 vs. CML 2) were (28.67±5.54 vs24.00 ± 4.80 t=2.121, p-value=0.039*), (0.94±0.31vs1.25 ± 0.6 t=-2.061, p-value=0.045*) and (927.09±488.17vs1426.25±630.45 t=-2.410, p-value=0.020*) respectively. Serum TSH correlated positively with Sokal score (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.